Lannett Looks To Transform Company With Five Pipeline Assets

As Company Reports Another Low Financial Quarter

With five “large, durable assets” in its pipeline, Lannett is confident that post approval these products have the potential to transform the company. This includes the generic version of Boehringer Ingelheim’s Spiriva Handihaler (tiotropium bromide) recently added to Lannett’s respiratory generics portfolio. 

strategy
Lannett expects five approvals by 2025 • Source: Alamy

More from Biosimilars

More from Products